Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DDX17

Gene summary for DDX17

Gene summary.

Gene information	Species	Human
	Gene symbol	DDX17
	Gene ID	10521
	Gene name	DEAD-box helicase 17
	Gene Alias	P72
	Cytomap	22q13.1
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	A0A1W2PQ51

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10521	DDX17	P2_cSCC	Human	Skin	cSCC	1.83e-16	7.91e-01	-0.024
10521	DDX17	P4_cSCC	Human	Skin	cSCC	4.58e-19	6.02e-01	-0.00290000000000005
10521	DDX17	P10_cSCC	Human	Skin	cSCC	8.09e-31	1.18e+00	0.1017
10521	DDX17	cSCC_p7	Human	Skin	cSCC	4.33e-02	1.20e-01	-0.2332
10521	DDX17	cSCC_p8	Human	Skin	cSCC	3.21e-05	2.72e-02	-0.1971
10521	DDX17	cSCC_p9	Human	Skin	cSCC	8.21e-03	-1.81e-02	-0.1991
10521	DDX17	Adj_PTCwithHT_6	Human	Thyroid	HT	2.07e-24	-7.72e-01	0.02
10521	DDX17	Adj_PTCwithHT_8	Human	Thyroid	HT	1.58e-15	-7.38e-01	0.0267
10521	DDX17	PTCwithHT_1	Human	Thyroid	HT	7.91e-11	-8.72e-01	0.0238
10521	DDX17	PTCwithHT_6	Human	Thyroid	HT	8.86e-23	-7.65e-01	0.02
10521	DDX17	PTCwithHT_8	Human	Thyroid	HT	6.48e-14	-6.46e-01	0.0351
10521	DDX17	PTCwithoutHT_2	Human	Thyroid	PTC	7.99e-21	-7.65e-01	0.0419
10521	DDX17	PTCwithoutHT_7	Human	Thyroid	PTC	8.54e-07	-7.85e-01	0.0381
10521	DDX17	male-WTA	Human	Thyroid	PTC	3.78e-65	5.88e-01	0.1037
10521	DDX17	PTC01	Human	Thyroid	PTC	1.45e-10	6.21e-01	0.1899
10521	DDX17	PTC03	Human	Thyroid	PTC	3.73e-12	1.33e+00	0.1784
10521	DDX17	PTC04	Human	Thyroid	PTC	2.70e-68	1.71e+00	0.1927
10521	DDX17	PTC05	Human	Thyroid	PTC	3.06e-25	1.79e+00	0.2065
10521	DDX17	PTC06	Human	Thyroid	PTC	1.41e-67	2.34e+00	0.2057
10521	DDX17	PTC07	Human	Thyroid	PTC	7.26e-86	1.90e+00	0.2044

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00226139	Breast	Precancer	ribonucleoprotein complex biogenesis	79/1080	463/18723	2.11e-18	1.03e-15	79
GO:00422549	Breast	Precancer	ribosome biogenesis	52/1080	299/18723	7.35e-13	1.51e-10	52
GO:00083809	Breast	Precancer	RNA splicing	65/1080	434/18723	1.27e-12	2.53e-10	65
GO:00434849	Breast	Precancer	regulation of RNA splicing	34/1080	148/18723	2.66e-12	4.75e-10	34
GO:00003759	Breast	Precancer	RNA splicing, via transesterification reactions	52/1080	324/18723	1.74e-11	2.22e-09	52
GO:00485459	Breast	Precancer	response to steroid hormone	53/1080	339/18723	3.07e-11	3.66e-09	53
GO:00003779	Breast	Precancer	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00003989	Breast	Precancer	mRNA splicing, via spliceosome	51/1080	320/18723	3.55e-11	4.04e-09	51
GO:00480249	Breast	Precancer	regulation of mRNA splicing, via spliceosome	22/1080	101/18723	5.29e-08	3.18e-06	22
GO:00063646	Breast	Precancer	rRNA processing	35/1080	225/18723	7.90e-08	4.60e-06	35
GO:00160726	Breast	Precancer	rRNA metabolic process	36/1080	236/18723	8.59e-08	4.84e-06	36
GO:19033118	Breast	Precancer	regulation of mRNA metabolic process	38/1080	288/18723	1.63e-06	5.97e-05	38
GO:00506848	Breast	Precancer	regulation of mRNA processing	23/1080	137/18723	3.49e-06	1.13e-04	23
GO:00713838	Breast	Precancer	cellular response to steroid hormone stimulus	28/1080	204/18723	1.78e-05	4.26e-04	28
GO:00003808	Breast	Precancer	alternative mRNA splicing, via spliceosome	15/1080	77/18723	2.86e-05	6.37e-04	15
GO:00003818	Breast	Precancer	regulation of alternative mRNA splicing, via spliceosome	13/1080	60/18723	2.98e-05	6.58e-04	13
GO:00344705	Breast	Precancer	ncRNA processing	42/1080	395/18723	9.91e-05	1.83e-03	42
GO:00305217	Breast	Precancer	androgen receptor signaling pathway	10/1080	44/18723	1.61e-04	2.69e-03	10
GO:00305187	Breast	Precancer	intracellular steroid hormone receptor signaling pathway	16/1080	116/18723	1.01e-03	1.13e-02	16
GO:00346604	Breast	Precancer	ncRNA metabolic process	45/1080	485/18723	1.15e-03	1.26e-02	45

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DDX17

SNV

Missense_Mutation

novel

c.793N>T

p.Asp265Tyr

p.D265Y

protein_coding

tolerated(0.78)

benign(0.018)

TCGA-A2-A0ER-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

DDX17

SNV

Missense_Mutation

novel

c.1427N>G

p.Asp476Gly

p.D476G

protein_coding

deleterious(0)

probably_damaging(0.916)

TCGA-AQ-A7U7-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Targeted Molecular therapy

rituximab

DDX17

SNV

Missense_Mutation

c.1262C>A

p.Thr421Lys

p.T421K

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A0H3-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DDX17

SNV

Missense_Mutation

c.815N>C

p.Arg272Thr

p.R272T

protein_coding

deleterious(0.01)

probably_damaging(0.998)

TCGA-BH-A1FC-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DDX17

SNV

Missense_Mutation

rs762058898

c.1963N>G

p.Gln655Glu

p.Q655E

protein_coding

tolerated_low_confidence(0.14)

benign(0.014)

TCGA-EW-A1J5-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

DDX17

insertion

Frame_Shift_Ins

novel

c.1168_1169insAGCTT

p.Ile390LysfsTer6

p.I390Kfs*6

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

DDX17

insertion

In_Frame_Ins

novel

c.1166_1167insAACAAAACAAAACTTAGC

p.Asn389delinsLysThrLysGlnAsnLeuAla

p.N389delinsKTKQNLA

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

DDX17

insertion

Frame_Shift_Ins

novel

c.946_947insAG

p.Leu316GlnfsTer39

p.L316Qfs*39

protein_coding

TCGA-A8-A07O-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

DDX17

insertion

Nonsense_Mutation

novel

c.945_946insTTGAAATTTTAACATGGTTATGTAAA

p.Arg317LysfsTer3

p.R317Kfs*3

protein_coding

TCGA-A8-A07O-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

DDX17

insertion

Nonsense_Mutation

novel

c.942_943insTTGTTGGTCATGTTTTCAGGTTGATCCAACTAATGG

p.Thr314_Asn315insLeuLeuValMetPheSerGlyTerSerAsnTerTrp

p.T314_N315insLLVMFSG*SN*W

protein_coding

TCGA-AN-A0FN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1